- Sung-wuk Kim, DDS
Dr. Sung-wuk Kim has served as Chairman of the Board of Directors and Chief Executive Officer (CEO) since the founding of ImmunoMet Therapeutics, a spinoff of HanAll Biopharma in July 2015. Dr. Kim was previously the CEO of HanAll Biopharma, and during his 12 years in various executive positions, he led a variety of new drug development programs including autoimmune diseases, fibrosis and metabolic diseases. He also pioneered an OXPHOS inhibitor research platform that is designed to target cancer metabolism, which has produced ImmunoMet’s lead drug candidate, IM156. Dr. Kim is an entrepreneur and accomplished inventor, who has made significant contributions to advance drug development, receiving more than 30 patents in a broad range of areas which include formulation, biologics and small molecule drugs.
Dr. Kim has also currently served on the Board of Directors of HanAll Biopharma since 2003 and as Chair of the R&D Committee of Daewoong Pharma Group since 2015. Previously, he served on the Boards of Directors of Humasis Inc, a diagnostics kit development company from 2002 to 2015 and Hangen Biotech, a RSV vaccine development company from 2002 to 2004. Before devoting his career to drug development, Dr. Kim was the founder of an IT entrepreneurial company, Freechal Inc, first XML platform internet community service provider, in 1999 and served on its Board of Directors until 2002.
Dr. Kim earned his Doctorate of Dental Surgery from Yonsei University in Korea.
- Sungsoo Koh, Ph.D.
As the CFO of ImmunoMet, Dr. Koh brings 40 years of leadership and expertise in corporate research
and finances and M&A. Dr. Koh also currently serves as the CEO of Intercapital Ltd., an investment
firm he founded in 1997 and has established his leadership position in corporate growth strategy
by closing mergers and acquisitions, financing deals, spin-offs, and listings for a number of companies
in pharmaceuticals, biotech, high-tech and telecommunications sectors. Prior to Intercapital,
Dr. Koh led the international business operation and equity research division of Hanhwa Securities. He began his career as an investment analyst of the electronics and pharmaceutical industries with Dongsuh Securities Ltd and started to develop his leadership in investment, international business operations and debt financing at the London office of Dongsuh Securities, which he established in 1985.Dr. Koh received his Ph.D. in Finance from City University London and MBA from University of Pittsburgh.
- Benjamin R. Cowen, PhD, MBA
Dr. Cowen has 20 years experience working with private, early-stage biotechnology companies and public companies including, Shire and Merck, where he held a of number management positions and received recognition for leading high-performance teams and successfully completing key business development transactions. Dr. Cowen most recently served as the Vice President of Corporate Development at Milestone Pharmaceuticals, where he played a key role in a Series B financing and was responsible for business development and commercial activities. Dr. Cowen has also served on Atrin Pharmaceuticals’ Board of Directors since its inception in 2012. Dr. Cowen received his Ph.D. from University of Illinois at Urbana Champaign, his MBA from Carnegie Mellon University, his BA at Brandeis University and was an NIH Post-Doctoral Fellow at the Univ of Pennsylvania.
- Bryan (Hong Woo) Kim, Ph.D.
VP Head of Chemistry
Prior to joining ImmunoMet, Dr. Kim served as the Head of the New Drug Development Team at HanAll Biopharma for 3 years. The key responsibilities during his tenure at HanAll were taking a lead in medicinal chemistry for development of drugs targeting cancer metabolism and managing the medicinal chemistry team. As a medicinal chemist, he has 17 years of working experience in antiviral, oncology and immunology drugs and has shown successful leadership in projects ranging from lead discovery to clinical trials in several startup biotech companies including Ardea Biosciences and Genosco. Bryan obtained his Ph.D. in organic chemistry from the University of Nebraska, Lincoln, for work on the synthesis and biological evaluation of the heavily fluorinated hexose and nucleoside analogues.
- Sanghee Yoo, Ph.D.
VP Head of Biology
Prior to joining ImmunoMet, Dr. Yoo served as the Head of the New Drug Development Team at HanAll Biopharma, leading and managing drug development projects targeting cancer metabolism and fibrosis. She has more than 20 years of working experiences in cystic fibrosis, pain, and oncology and has shown successful leadership in projects ranging from target selection to clinical candidate nomination in several biotech companies including ProQR (Netherlands), Vertex Pharmaceuticals, Aurora Biosciences and Arcaris. Sanghee obtained her Ph.D. in biochemistry from the University of Utah, Salt Lake City, for work on protein-protein interactions between human cyclophilin A and HIV-1 capsid.
- Anthony A. Hörning
Business Advisor (part Time)
In 2014, Anthony A. Hörning founded Strategic Transactions Advisory AG (Basel, Switzerland) and since 2015, has been a Senior Advisor at Vantage Partners LLP (Boston, USA).
As Head of Alliance Management, he was in charge of the preparation, launch and ongoing implementation, as well as of all renegotiations, of Novartis Pharma global alliances and created a widely recognized alliance skills training program. He served for many years as a member of the board of the “Association of Strategic Alliance Professionals“. Prior to his career in Business Development & Licensing, Mr. Hörning was CFO of Novartis in Brazil and Head of Investor Relations & Capital Markets for the former Sandoz AG in Switzerland. He gained his initial training in international capital markets as a Vice-President with JPMorgan. He holds a Masters Degree in Business Administration from the University of Zürich.
Copyright © ImmunoMet. All rights reserved.